Shares of Teva are up slightly today after the company announced the FDA approved its pain management drug.
- American City Business Journals•yesterday
The Food and Drug Administration granted marketing approval Wednesday to Vantrela ER, an extended release pain medicine developed by Teva Pharmaceutical Industries that is formulated using the company’s proprietary abuse deterrence technology. Vantrela ER was approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Company officials said the product’s abuse-deterrent properties that are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.
- Business Wire•yesterdayTeva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology
Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration approved VANTRELATM ER extended-release tablets formulated with Teva’s proprietary abuse deterrence technology.
TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.61 - 34.07|
|52 Week Range||33.56 - 64.31|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.45|
|Dividend & Yield||1.36 (4.03%)|
|1y Target Est||N/A|